公开(公告)号：JPH08245693A

公开(公告)日：1996-09-24

申请号：JP27319595

申请日：1995-10-20

申请人： IAF BIOCHEM INT

发明人： FURANSESUKO BERIINI ,  JIERUBE DOWANNU ,  MAASHIYARU RAKUROWA

IPC分类号： G01N33/53 ,  A61K38/00 ,  A61K39/00 ,  A61K39/21 ,  A61P31/12 ,  A61P31/18 ,  C07K1/04 ,  C07K1/06 ,  C07K1/10 ,  C07K1/107 ,  C07K1/20 ,  C07K7/06 ,  C07K7/08 ,  C07K7/64 ,  C07K14/00 ,  C07K14/155 ,  C07K14/16 ,  C07K16/00 ,  C12P21/08 ,  G01N33/569

公开(公告)号：JP2001226268A

公开(公告)日：2001-08-21

申请号：JP2001046491

申请日：2001-02-22

申请人： IAF BIOCHEM INT

发明人： BELLEAU BERNARD ,  NGUYEN-BA NGHE

IPC分类号： A61K45/00 ,  A61K31/00 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/529 ,  A61K31/53 ,  A61P1/00 ,  A61P1/16 ,  A61P31/00 ,  A61P31/20 ,  C07D411/04 ,  C07D473/16 ,  C07D473/18 ,  C07D473/32 ,  C07D473/34 ,  C07D473/40 ,  C07D487/04

摘要： PROBLEM TO BE SOLVED: To provide the use of analogue of a nucleoside in the treatment of viral infection. SOLUTION: This medicinal composition for treating the infection of hepatitis B contains a pharmaceutically acceptable carrier, cis-2-hydroxymethyl-5-(5'- fluorocytosion-1'-yl)-1,3-oxathiolane or trans-2-hydroxumethyl-5-(5'-flurocytosin-1'- yl)-1,3-oxathiolane in the shape of a racemic mixture or a signal enantiomer, or a pharmaceutically acceptable salt or a mixture thereof, and at least one therapeutically active antiviral agent.

公开(公告)号：JPH11322608A

公开(公告)日：1999-11-24

申请号：JP9873699

申请日：1999-04-06

申请人： IAF BIOCHEM INT

发明人： BELLEAU BERNARD ,  NGUYEN-BA NGHE

IPC分类号： A61K45/00 ,  A61K31/00 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/529 ,  A61K31/53 ,  A61P1/00 ,  A61P1/16 ,  A61P31/00 ,  A61P31/20 ,  C07D411/04 ,  C07D473/16 ,  C07D473/18 ,  C07D473/32 ,  C07D473/34 ,  C07D473/40 ,  C07D487/04

摘要： PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition useful for treatment of viral infection, especially treatment of hepatitis B by using an oxathiolane nucleoside analog. SOLUTION: This pharmaceutical composition for treatment of infection of hepatitis B comprises a carrier and a compound of formula I R1 is H or an acyl; R2 is a group of formula II [R3 is H or a (hetero atom-substituted) 1-6C alkyl; R4 is H, a 1-3C alkyl or the like] or a group of formula III (X and Y are each a halogen, amino or OH; when R1 is H and Z is S, R2 is cytosine or the like and when R2 is cytosine, the compound has trans configuration)} or its salt [e.g. cis and trans-2-benzoyloxymethyl-5-(N'4 -acetyl-5'-fluoro-cytosin-1'- yl)-1,3-oxathiolane].

公开(公告)号：JPH10139668A

公开(公告)日：1998-05-26

申请号：JP30451697

申请日：1997-11-06

申请人： IAF BIOCHEM INT

发明人： TARECK MANSOUR ,  TSE ALLAN H L

IPC分类号： C07D405/04 ,  A01N43/04 ,  A61K20060101 ,  A61K31/505 ,  A61K31/70 ,  A61K31/7115 ,  A61P1/16 ,  A61P31/12 ,  C07H20060101 ,  C07H19/00 ,  C07H19/073 ,  C07H19/09

摘要： PROBLEM TO BE SOLVED: To use a specific enantiomer in treatment of virus infection, especially HIV infection, B-type hepatitis infection due to virus. SOLUTION: A β-L-enantiomer of the formula or its pharmaceutically permissible derivative is used for treatment of infection due to virus. Furthermore, a daily dose of the compound is about 0.1mg to at least 750mg/kg.weight and the compound is administered in an amount of about 10-1,500mg in dosage unit form and the compound is preferably used together with a pharmaceutically permissible carrier, other therapeutically active medicine, specifically, an antiviral agent such as AZT or 3TCTM.

公开(公告)号：JP2000143662A

公开(公告)日：2000-05-26

申请号：JP37006399

申请日：1999-12-27

申请人： IAF BIOCHEM INT

发明人： BELLEAU BERNARD ,  NGUYEN-BA NGHE

IPC分类号： C07D411/04 ,  A61K20060101 ,  A61K31/39 ,  A61K31/41 ,  A61K31/42 ,  A61K31/445 ,  A61K31/495 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/53 ,  A61K31/54 ,  A61P31/12 ,  A61P31/18 ,  C07B53/00 ,  C07D20060101 ,  C07D239/10 ,  C07D239/36 ,  C07D239/47 ,  C07D239/54 ,  C07D263/06 ,  C07D327/04 ,  C07D405/04 ,  C07D411/02 ,  C07D411/14 ,  C07D473/00 ,  C07D473/04 ,  C07D473/16 ,  C07D473/18 ,  C07D473/28 ,  C07D473/30 ,  C07D473/32 ,  C07D473/34 ,  C07D473/40 ,  C07D487/04 ,  C07H20060101

摘要： PROBLEM TO BE SOLVED: To provide a new substituted 1,3-oxathiolane compound capable of being easily synthesized, having low toxicity, and useful as an effective anti- human immunodeficiency virus(anti-HIV) compound. SOLUTION: A single enantiomer or the enantiomer mixture of a cis-2- hydroxymethyl-5-(thymin-N-1'-yl)-1,3-oxathiolane compound of formula I [R1 is H; Z is S, S=O or SO2; R2 is a group of formula II (R3 is H or a 1-6C alkyl) or the like], for example, 2-benzoyloxymethyl-5-(N4'-acetyl-cytosin-1'-yl)-1,3- oxothiolane. The compound of formula I, for example, can be obtained by reacting a 1,3-oxathiolane of formula III (L is preferably an alkoxyl, carbonyl or a halogen or the like), which is obtained from a relevant aldehyde and mercaptoacetal, with a relevant purine base or pyrimidine base using a Lewis acid or trimethylsilyl triflate in a compatible solvent, such as methyl chloride.

公开(公告)号：JPH05186463A

公开(公告)日：1993-07-27

申请号：JP12916392

申请日：1992-05-21

申请人： IAF BIOCHEM INT

发明人： TAREKU MANSUURU ,  ARAN EICHI ERU TSUE

IPC分类号： C07H19/00 ,  A61K31/513 ,  A61P31/12 ,  B01J31/02 ,  C07B53/00 ,  C07B61/00 ,  C07C13/10 ,  C07D20060101 ,  C07D207/00 ,  C07D231/04 ,  C07D233/02 ,  C07D261/02 ,  C07D263/04 ,  C07D275/02 ,  C07D277/04 ,  C07D285/04 ,  C07D291/04 ,  C07D307/04 ,  C07D307/16 ,  C07D307/18 ,  C07D307/24 ,  C07D317/08 ,  C07D317/24 ,  C07D317/32 ,  C07D317/34 ,  C07D323/02 ,  C07D327/04 ,  C07D333/48 ,  C07D339/02 ,  C07D339/06 ,  C07D341/00 ,  C07D403/04 ,  C07D405/04 ,  C07D407/04 ,  C07D409/04 ,  C07D411/04 ,  C07D411/12 ,  C07D411/14 ,  C07D413/04 ,  C07D419/04 ,  C07D471/00 ,  C07D473/00 ,  C07D473/06 ,  C07D473/30 ,  C07D473/34 ,  C07H19/04 ,  C07H19/06 ,  C07H19/16

公开(公告)号：JPH037282A

公开(公告)日：1991-01-14

申请号：JP3132490

申请日：1990-02-08

申请人： IAF BIOCHEM INT

发明人： BERUNAARU BEROO ,  PIERETSUTO BEROO ,  NIE NIEIENNBA

IPC分类号： C07D411/04 ,  A61K20060101 ,  A61K31/39 ,  A61K31/41 ,  A61K31/42 ,  A61K31/445 ,  A61K31/495 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/53 ,  A61K31/54 ,  A61P31/12 ,  A61P31/18 ,  C07B53/00 ,  C07D20060101 ,  C07D239/10 ,  C07D239/36 ,  C07D239/47 ,  C07D239/54 ,  C07D263/06 ,  C07D327/04 ,  C07D405/04 ,  C07D411/02 ,  C07D411/14 ,  C07D473/00 ,  C07D473/04 ,  C07D473/16 ,  C07D473/18 ,  C07D473/28 ,  C07D473/30 ,  C07D473/32 ,  C07D473/34 ,  C07D473/40 ,  C07D487/04 ,  C07H20060101

公开(公告)号：JPH01316375A

公开(公告)日：1989-12-21

申请号：JP8989389

申请日：1989-04-11

申请人： IAF BIOCHEM INT

发明人： BERUNAADO BEROO ,  DEIRITSUPU DEIKISHITSUTO ,  NUGE NUGUIENNBAA

IPC分类号： C07D473/16 ,  A61K31/505 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61P31/12 ,  A61P31/18 ,  A61P37/00 ,  C07D327/04 ,  C07D405/04 ,  C07D411/04 ,  C07D411/14 ,  C07D473/00 ,  C07D473/18 ,  C07D473/32 ,  C07D473/34 ,  C07D473/40

公开(公告)号：JP2003189879A

公开(公告)日：2003-07-08

申请号：JP2002269639

申请日：2002-09-17

申请人： IAF BIOCHEM INT

发明人： BRODEUR BERNARD R ,  MARTIN DENIS ,  HAMEL JOSEE ,  RIOUX CLEMENT

IPC分类号： G01N33/53 ,  A61K38/00 ,  A61K39/00 ,  A61K39/095 ,  A61K39/395 ,  A61K39/40 ,  A61K49/00 ,  A61P31/04 ,  A61P43/00 ,  C07K20060101 ,  C07K14/195 ,  C07K14/22 ,  C07K16/12 ,  C12N1/21 ,  C12N15/02 ,  C12N15/09 ,  C12N15/16 ,  C12N15/31 ,  C12N15/70 ,  C12P19/34 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/04 ,  C12Q1/68 ,  C12R1/01 ,  C12R1/19 ,  C12R1/36 ,  G01N33/15 ,  G01N33/531 ,  G01N33/564 ,  G01N33/566 ,  G01N33/569 ,  G01N33/577

摘要： PROBLEM TO BE SOLVED: To provide a highly conserved immunologically accessible antigen at the surface of Neisseria meningitidis organisms, and immunotherapeutic, prophylactic and diagnostic compositions useful in the treatment, prevention and diagnosis of Neisseria meningitidis disease. SOLUTION: This isolated antigen or a fragment thereof is immunologically bondable to ≥50% known strain of the Neisseria meningitidis. The protease K resistant surface protein of the Neissheria meningitidis having an apparent molecular weight of 22 kDa, the corresponding base sequence and the derived amino acid sequence, the recombinant DNA method for the production of the Neissieria meningitidis 22 kDa surface protein, and the antibody that binds to the Neisseria meningitidis 22 kDa surface protein are also provided. COPYRIGHT: (C)2003,JPO

公开(公告)号：JP2001226373A

公开(公告)日：2001-08-21

申请号：JP2001059730

申请日：2001-03-05

申请人： IAF BIOCHEM INT

发明人： BELLEAU BERNARD ,  NGUYEN-BA NGHE

IPC分类号： C07D411/04 ,  A61K20060101 ,  A61K31/39 ,  A61K31/41 ,  A61K31/42 ,  A61K31/445 ,  A61K31/495 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/53 ,  A61K31/54 ,  A61P31/12 ,  A61P31/18 ,  C07B53/00 ,  C07D20060101 ,  C07D239/10 ,  C07D239/36 ,  C07D239/47 ,  C07D239/54 ,  C07D263/06 ,  C07D327/04 ,  C07D405/04 ,  C07D411/02 ,  C07D411/14 ,  C07D473/00 ,  C07D473/04 ,  C07D473/16 ,  C07D473/18 ,  C07D473/28 ,  C07D473/30 ,  C07D473/32 ,  C07D473/34 ,  C07D473/40 ,  C07D487/04 ,  C07H20060101

摘要： PROBLEM TO BE SOLVED: To provide a new substituted 1,3-oxathiolane cyclic compound having pharmacological activity. SOLUTION: This new compound is a cis-2-hydroxymethyl-5-(thymine-N-1'- yl)-1,3-oxathiolane compound in the form of a single enantiomer or an enantiomeric mixture.